Three CRO Enterprise Partners expand agreements with DATATRAK

DATATRAK International, Inc. (OTCQX: DTRK), the leader in developing cloud-based, unified eClinical® technologies and delivering related services for the clinical trials industry, today announced three CRO Enterprise Partners have expanded their agreements. These industry-leading organizations have chosen to boost their global licensing capacity and extended their relationship with DATATRAK.

"These partners have challenged the norm in our industry and experienced the rewards of a unified platform," said Laurence P. Birch, Chairman and CEO, DATATRAK. "Complexities once considered unavoidable, including data integration, are a thing of the past when organizations choose DATATRAK. Benefits that were previously considered futuristic, like Cross-Study real time data reporting, are available right now from DATATRAK. We are transforming how clinical research is managed, improving patient safety by getting the right information to the right person to make informed decisions faster."

The latest enhancements to the DATATRAK ONE® Unified Experience™ challenge the industry to reevaluate their expectations of eClinical systems. The Cross-Study Manager delivers real-time enterprise-wide reporting and analysis. The Scheduler removes the redundancy of establishing repeated actions, among other benefits.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.